BNP Paribas Asset Management
LGND icon

BNP Paribas Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

BNP Paribas Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.1K Buy
321
+63
+24% +$12.5K ﹤0.01% 1661
2025
Q4 		$49K Buy
258
+83
+47% +$15.9K ﹤0.01% 1673
2025
Q3 		$31K Sell
175
-8
-4% -$1.19K ﹤0.01% 1227
2025
Q2 		$21K Buy
+183
New +$19.6K ﹤0.01% 1483

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

BNP Paribas Asset Management's LGND Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 24% in Q1 2026, buying an estimated $12.5K and bringing the position to 321 shares worth $64.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

BNP Paribas Asset Management first reported a position in LGND in Q2 2025 and has held it in 4 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • BNP Paribas Asset Management held 321 shares of Ligand Pharmaceuticals worth $64.1K as of Q1 2026.
  • BNP Paribas Asset Management bought 63 Ligand Pharmaceuticals shares in Q1 2026, an estimated $12.5K.
  • Ligand Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1661 holding.
  • BNP Paribas Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.